ArriVent BioPharma, Inc.
AVBP
$20.82
-$0.35-1.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -80.49M | -81.05M | -74.89M | -74.58M | -69.33M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.21M | 2.58M | 1.93M | 1.35M | 895.00K |
| Change in Net Operating Assets | 7.07M | 9.50M | 4.89M | 15.64M | 12.60M |
| Cash from Operations | -70.21M | -68.97M | -68.07M | -57.59M | -55.84M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -192.47M | 25.00M | 25.00M | 0.00 | 0.00 |
| Cash from Investing | -192.47M | 25.00M | 25.00M | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 186.58M | 186.81M | 186.32M | 185.96M | 354.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 0.00 | 44.94M |
| Repurchase of Preferred Stock | -- | -- | -- | -24.00K | -24.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1.34M | -2.41M | -2.41M | -2.41M |
| Cash from Financing | 186.58M | 185.47M | 183.91M | 183.52M | 42.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.10M | 141.50M | 140.84M | 125.93M | -12.98M |